Completed
Efficacy and Safety of Omalizumab in Adults (18-70 Years) With Moderate to Severe Chronic Urticaria
NCT00481676
- Conditions
- Chronic Disease, Chronic Urticaria, Disease Attributes, +10 more
- Locations
-
- Novartis Investigative Site Berlin, Germany
- Novartis Investigative Site Bonn, Germany
- Novartis Investigative Site Cologne, Germany
- Novartis Investigative Site Dresden, Germany